



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

## NOTICE OF ALLOWANCE AND FEE(S) DUE

7590

12/18/2009

Dr. Judy Jarecki-Black  
Merial Limited  
3239 Satellite Boulevard  
Duluth, GA 30096

EXAMINER

HENRY, MICHAEL C

ART UNIT

PAPER NUMBER

1623

DATE MAILED: 12/18/2009

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,715	02/17/2006	Fiona Murphy Kessabi	MER 70305	7073

TITLE OF INVENTION: avermectins and avermectin monosaccharides substituted in the 4'-and 4" position having pesticidal properties

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	03/18/2010

**THE APPLICATION IDENTIFIED ABOVE HAS BEEN EXAMINED AND IS ALLOWED FOR ISSUANCE AS A PATENT. PROSECUTION ON THE MERITS IS CLOSED. THIS NOTICE OF ALLOWANCE IS NOT A GRANT OF PATENT RIGHTS. THIS APPLICATION IS SUBJECT TO WITHDRAWAL FROM ISSUE AT THE INITIATIVE OF THE OFFICE OR UPON PETITION BY THE APPLICANT. SEE 37 CFR 1.313 AND MPEP 1308.**

**THE ISSUE FEE AND PUBLICATION FEE (IF REQUIRED) MUST BE PAID WITHIN THREE MONTHS FROM THE MAILING DATE OF THIS NOTICE OR THIS APPLICATION SHALL BE REGARDED AS ABANDONED. THIS STATUTORY PERIOD CANNOT BE EXTENDED. SEE 35 U.S.C. 151. THE ISSUE FEE DUE INDICATED ABOVE DOES NOT REFLECT A CREDIT FOR ANY PREVIOUSLY PAID ISSUE FEE IN THIS APPLICATION. IF AN ISSUE FEE HAS PREVIOUSLY BEEN PAID IN THIS APPLICATION (AS SHOWN ABOVE), THE RETURN OF PART B OF THIS FORM WILL BE CONSIDERED A REQUEST TO REAPPLY THE PREVIOUSLY PAID ISSUE FEE TOWARD THE ISSUE FEE NOW DUE.**

**HOW TO REPLY TO THIS NOTICE:**

I. Review the SMALL ENTITY status shown above.

If the SMALL ENTITY is shown as YES, verify your current SMALL ENTITY status:

A. If the status is the same, pay the TOTAL FEE(S) DUE shown above.

B. If the status above is to be removed, check box 5b on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and twice the amount of the ISSUE FEE shown above, or

If the SMALL ENTITY is shown as NO:

A. Pay TOTAL FEE(S) DUE shown above, or

B. If applicant claimed SMALL ENTITY status before, or is now claiming SMALL ENTITY status, check box 5a on Part B - Fee(s) Transmittal and pay the PUBLICATION FEE (if required) and 1/2 the ISSUE FEE shown above.

II. PART B - FEE(S) TRANSMITTAL, or its equivalent, must be completed and returned to the United States Patent and Trademark Office (USPTO) with your ISSUE FEE and PUBLICATION FEE (if required). If you are charging the fee(s) to your deposit account, section "4b" of Part B - Fee(s) Transmittal should be completed and an extra copy of the form should be submitted. If an equivalent of Part B is filed, a request to reapply a previously paid issue fee must be clearly made, and delays in processing may occur due to the difficulty in recognizing the paper as an equivalent of Part B.

III. All communications regarding this application must give the application number. Please direct all communications prior to issuance to Mail Stop ISSUE FEE unless advised to the contrary.

**IMPORTANT REMINDER: Utility patents issuing on applications filed on or after Dec. 12, 1980 may require payment of maintenance fees. It is patentee's responsibility to ensure timely payment of maintenance fees when due.**

## PART B - FEE(S) TRANSMITTAL

**Complete and send this form, together with applicable fee(s), to:** **Mail Stop ISSUE FEE**  
**Commissioner for Patents**  
**P.O. Box 1450**  
**Alexandria, Virginia 22313-1450**  
**or Fax (571)-273-2885**

**INSTRUCTIONS:** This form should be used for transmitting the ISSUE FEE and PUBLICATION FEE (if required). Blocks 1 through 5 should be completed where appropriate. All further correspondence including the Patent, advance orders and notification of maintenance fees will be mailed to the current correspondence address as indicated unless corrected below or directed otherwise in Block 1, by (a) specifying a new correspondence address; and/or (b) indicating a separate "FEE ADDRESS" for maintenance fee notifications.

CURRENT CORRESPONDENCE ADDRESS (Note: Use Block 1 for any change of address)

7590                    12/18/2009

Dr. Judy Jarecki-Black  
Merial Limited  
3239 Satellite Boulevard  
Duluth, GA 30096

Note: A certificate of mailing can only be used for domestic mailings of the Fee(s) Transmittal. This certificate cannot be used for any other accompanying papers. Each additional paper, such as an assignment or formal drawing, must have its own certificate of mailing or transmission.

### **Certificate of Mailing or Transmission**

I hereby certify that this Fee(s) Transmittal is being deposited with the United States Postal Service with sufficient postage for first class mail in an envelope addressed to the Mail Stop ISSUE FEE address above, or being facsimile transmitted to the USPTO (571) 273-2885, on the date indicated below.

(Depositor's name)

(Signature)

(Date)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,715	02/17/2006	Fiona Murphy Kessabi	MER 70305	7073

**TITLE OF INVENTION:** AVERMECTINS AND AVERMECTIN MONOSACCHARIDES SUBSTITUTED IN THE 4'-AND 4" POSITION HAVING PESTICIDAL PROPERTIES

APPLN. TYPE	SMALL ENTITY	ISSUE FEE DUE	PUBLICATION FEE DUE	PREV. PAID ISSUE FEE	TOTAL FEE(S) DUE	DATE DUE
nonprovisional	NO	\$1510	\$300	\$0	\$1810	03/18/2010
EXAMINER	ART UNIT	CLASS-SUBCLASS				
HENRY, MICHAEL C		1623	514-030000			

1. Change of correspondence address or indication of "Fee Address" (37 CFR 1.363).

- Change of correspondence address (or Change of Correspondence Address form PTO/SB/122) attached.  
 "Fee Address" indication (or "Fee Address" Indication form PTO/SB/47; Rev 03-02 or more recent) attached. **Use of a Customer Number is required.**

2. For printing on the patent front page, list

- (1) the names of up to 3 registered patent attorneys or agents OR, alternatively,  
(2) the name of a single firm (having as a member a registered attorney or agent) and the names of up to 2 registered patent attorneys or agents. If no name is listed, no name will be printed.

1 \_\_\_\_\_  
2 \_\_\_\_\_  
3 \_\_\_\_\_

3. ASSIGNEE NAME AND RESIDENCE DATA TO BE PRINTED ON THE PATENT (print or type)

PLEASE NOTE: Unless an assignee is identified below, no assignee data will appear on the patent. If an assignee is identified below, the document has been filed for recordation as set forth in 37 CFR 3.11. Completion of this form is NOT a substitute for filing an assignment.

(A) NAME OF ASSIGNEE

(B) RESIDENCE: (CITY and STATE OR COUNTRY)

Please check the appropriate assignee category or categories (will not be printed on the patent):  Individual  Corporation or other private group entity  Government

4a. The following fee(s) are submitted:

- Issue Fee  
 Publication Fee (No small entity discount permitted)  
 Advance Order - # of Copies \_\_\_\_\_

4b. Payment of Fee(s): (Please first reapply any previously paid issue fee shown above)

- A check is enclosed.  
 Payment by credit card. Form PTO-2038 is attached.  
 The Director is hereby authorized to charge the required fee(s), any deficiency, or credit any overpayment, to Deposit Account Number \_\_\_\_\_ (enclose an extra copy of this form).

5. Change in Entity Status (from status indicated above)

- a. Applicant claims SMALL ENTITY status. See 37 CFR 1.27.  b. Applicant is no longer claiming SMALL ENTITY status. See 37 CFR 1.27(g)(2).

NOTE: The Issue Fee and Publication Fee (if required) will not be accepted from anyone other than the applicant; a registered attorney or agent; or the assignee or other party in interest as shown by the records of the United States Patent and Trademark Office.

Authorized Signature \_\_\_\_\_

Date \_\_\_\_\_

Typed or printed name \_\_\_\_\_

Registration No. \_\_\_\_\_

This collection of information is required by 37 CFR 1.311. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, Virginia 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
[www.uspto.gov](http://www.uspto.gov)

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/568,715	02/17/2006	Fiona Murphy Kessabi	MER 70305	7073
7590	12/18/2009			
Dr. Judy Jarecki-Black Merial Limited 3239 Satellite Boulevard Duluth, GA 30096				EXAMINER
				HENRY, MICHAEL C
			ART UNIT	PAPER NUMBER
			1623	
DATE MAILED: 12/18/2009				

## Determination of Patent Term Adjustment under 35 U.S.C. 154 (b)

(application filed on or after May 29, 2000)

The Patent Term Adjustment to date is 673 day(s). If the issue fee is paid on the date that is three months after the mailing date of this notice and the patent issues on the Tuesday before the date that is 28 weeks (six and a half months) after the mailing date of this notice, the Patent Term Adjustment will be 673 day(s).

If a Continued Prosecution Application (CPA) was filed in the above-identified application, the filing date that determines Patent Term Adjustment is the filing date of the most recent CPA.

Applicant will be able to obtain more detailed information by accessing the Patent Application Information Retrieval (PAIR) WEB site (<http://pair.uspto.gov>).

Any questions regarding the Patent Term Extension or Adjustment determination should be directed to the Office of Patent Legal Administration at (571)-272-7702. Questions relating to issue and publication fee payments should be directed to the Customer Service Center of the Office of Patent Publication at 1-(888)-786-0101 or (571)-272-4200.

<b>Notice of Allowability</b>	<b>Application No.</b>	<b>Applicant(s)</b>	
	10/568,715	KESSABI ET AL.	
	<b>Examiner</b>	<b>Art Unit</b>	
MICHAEL C. HENRY		1623	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1.  This communication is responsive to the amendment filed 08/31/09.
2.  The allowed claim(s) is/are 1-4, 7 and 9-22. These claims are renumbered 1-19, respectively.
3.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
  - a)  All    b)  Some\*    c)  None    of the:
    1.  Certified copies of the priority documents have been received.
    2.  Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
    3.  Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\* Certified copies not received: \_\_\_\_\_.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

**THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.**

4.  A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5.  CORRECTED DRAWINGS ( as "replacement sheets") must be submitted.
  - (a)  including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached
    - 1)  hereto or 2)  to Paper No./Mail Date \_\_\_\_\_.
  - (b)  including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date \_\_\_\_\_.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).
6.  DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

**Attachment(s)**

1.  Notice of References Cited (PTO-892)
2.  Notice of Draftsperson's Patent Drawing Review (PTO-948)
3.  Information Disclosure Statements (PTO/SB/08),  
Paper No./Mail Date \_\_\_\_\_
4.  Examiner's Comment Regarding Requirement for Deposit  
of Biological Material
5.  Notice of Informal Patent Application
6.  Interview Summary (PTO-413),  
Paper No./Mail Date \_\_\_\_\_.
7.  Examiner's Amendment/Comment
8.  Examiner's Statement of Reasons for Allowance
9.  Other \_\_\_\_\_.

/Shaojia Anna Jiang/  
Supervisory Patent Examiner, Art Unit 1623


***EXAMINER'S AMENDMENT***

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with John Esteban Ezcurra (Reg # 61,004) on 12/15/09.

The application has been amended as follows:

Claim 1 (Currently amended): A compound of the formula



wherein the bond between carbon atoms 22 and 23 is a single or double bond;

m is 0 or 1;

R<sub>1</sub> is C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl or C<sub>2</sub>-C<sub>12</sub>alkenyl; and either

(A) R<sub>2</sub> is -N(R<sub>3</sub>)R<sub>4</sub>, and

(1) X is O, wherein

Art Unit: 1623

R<sub>3</sub> is hydrogen, unsubstituted or mono- to pentasubstituted C<sub>1</sub>-C<sub>12</sub>alkyl, unsubstituted or mono- to pentasubstituted C<sub>3</sub>-C<sub>12</sub>cycloalkyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkenyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkynyl, aryl or heterocyclyl, and

R<sub>4</sub> is mono- to pentasubstituted C<sub>1</sub>-C<sub>12</sub>alkyl, unsubstituted or mono- to pentasubstituted C<sub>3</sub>-C<sub>12</sub>cycloalkyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkenyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkynyl, unsubstituted or mono- to trisubstituted heterocyclyl, unsubstituted or mono- to pentasubstituted aryl, NH<sub>2</sub>, NHC<sub>1</sub>-C<sub>12</sub>alkyl, N(C<sub>1</sub>-C<sub>12</sub>alkyl)<sub>2</sub>, C<sub>1</sub>-C<sub>6</sub>alkyl-N(C<sub>1</sub>-C<sub>12</sub>alkyl)<sub>2</sub>, -C<sub>4</sub>-C<sub>6</sub>alkyl-N<sup>+</sup>(C<sub>4</sub>-C<sub>12</sub>alkyl)<sub>3</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHC<sub>6</sub>H<sub>5</sub>, SO<sub>2</sub>Phenyl, SO<sub>2</sub>Benzyl, OH, -OC<sub>1</sub>-C<sub>12</sub>alkyl, -OC<sub>1</sub>-C<sub>12</sub>alkenyl or -OC<sub>1</sub>-C<sub>12</sub>alkynyl; or

- (2) X is S, wherein

R<sub>3</sub> is hydrogen, unsubstituted or mono- to pentasubstituted C<sub>1</sub>-C<sub>12</sub>alkyl, unsubstituted or mono- to pentasubstituted C<sub>3</sub>-C<sub>12</sub>cycloalkyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkenyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkynyl; aryl or heterocyclyl, and

R<sub>4</sub> is hydrogen, unsubstituted or mono- to pentasubstituted C<sub>1</sub>-C<sub>12</sub>alkyl, unsubstituted or mono- to pentasubstituted C<sub>3</sub>-C<sub>12</sub>cycloalkyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkenyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkynyl, unsubstituted or mono- to trisubstituted heterocyclyl, unsubstituted or mono- to pentasubstituted aryl, NH<sub>2</sub>, NHC<sub>1</sub>-C<sub>12</sub>alkyl, N(C<sub>1</sub>-C<sub>12</sub>alkyl)<sub>2</sub>, SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHC<sub>6</sub>H<sub>5</sub>, SO<sub>2</sub>Phenyl, SO<sub>2</sub>Benzyl, OH or -OC<sub>1</sub>-C<sub>12</sub>alkyl; or

- (3) X is O or S, wherein R<sub>3</sub> and R<sub>4</sub> together are a three- to seven-membered alkylene or a four- to seven-membered alkenylene bridge, in which a CH<sub>2</sub> group may be replaced by Θ, S, C=O or NR<sub>6</sub>;

in which the substituents of the alkyl-, alkenyl-, alkynyl-, alkylene-, alkenylene-, heterocyclyl-, aryl- and cycloalkyl-radicals mentioned under R<sub>3</sub> and R<sub>4</sub> are selected from the

Art Unit: 1623

group consisting of halogen, halo-C<sub>1</sub>-C<sub>2</sub>alkyl, CN, SCN, NO<sub>2</sub>, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl which is unsubstituted or substituted by one to three methyl groups; norbornylenyl; C<sub>3</sub>-C<sub>8</sub>cycloalkenyl which is unsubstituted or substituted by one to three methyl groups; C<sub>3</sub>-C<sub>8</sub>halocycloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>alkoxyC<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>3</sub>-C<sub>8</sub>cycloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio, C<sub>3</sub>-C<sub>8</sub>cycloalkylthio, C<sub>1</sub>-C<sub>12</sub>haloalkylthio, C<sub>1</sub>-C<sub>12</sub>alkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfinyl, C<sub>1</sub>-C<sub>12</sub>haloalkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfinyl, C<sub>1</sub>-C<sub>12</sub>alkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfonyl, C<sub>1</sub>-C<sub>12</sub>haloalkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfonyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, -N(R<sub>6</sub>)<sub>2</sub>, wherein the two R<sub>6</sub> are independent of each other; -C(=O)R<sub>7</sub>, -O-C(=O)R<sub>8</sub>, -NHC(=O)R<sub>7</sub>, -S-C(=S)R<sub>8</sub>, -P(=O)(OC<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -S(=O)<sub>2</sub>R<sub>11</sub>; -NH-S(=O)<sub>2</sub>R<sub>11</sub>, -OC(=O)-C<sub>1</sub>-C<sub>6</sub>alkyl-S(=O)<sub>2</sub>R<sub>11</sub>; heterocyclyl, aryloxy, benzyloxy, heterocyclyloxy, arylthio, benzylthio or heterocyclylthio, each of which may be mono- to pentasubstituted by substituents selected from the group consisting of OH, halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>haloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio, C<sub>1</sub>-C<sub>12</sub>haloalkylthio, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, dimethylamino-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, phenoxy, phenyl-C<sub>1</sub>-C<sub>6</sub>alkyl, methylenedioxy, -C(=O)R<sub>7</sub>, -O-C(=O)R<sub>8</sub>, -NH-C(=O)R<sub>8</sub>, -N(R<sub>10</sub>)<sub>2</sub>, wherein the two R<sub>10</sub> are independent of each other; C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>haloalkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfonyl, C<sub>1</sub>-C<sub>6</sub>haloalkylsulfonyl and C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfonyl; or

(B) R<sub>2</sub> is OR<sub>5</sub> and X is O or S, wherein R<sub>5</sub> is mono- to pentasubstituted C<sub>1</sub>-C<sub>12</sub>alkyl, unsubstituted or mono- to pentasubstituted C<sub>3</sub>-C<sub>12</sub>cycloalkyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkenyl, unsubstituted or mono- to pentasubstituted C<sub>2</sub>-C<sub>12</sub>alkynyl; in which the substituents of the alkyl-, alkenyl-, alkynyl-, alkylene-, alkenylene-, heterocyclyl-, aryl- and cycloalkyl-radicals mentioned under R<sub>3</sub>, R<sub>4</sub> and R<sub>5</sub> are selected from the group consisting of OH, halogen, halo-C<sub>1</sub>-C<sub>2</sub>alkyl, CN, SCN, NO<sub>2</sub>, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl which is unsubstituted or substituted by one to three methyl groups; norbornylenyl; C<sub>3</sub>-C<sub>8</sub>cycloalkenyl which is unsubstituted or substituted by one to three methyl groups; C<sub>3</sub>-C<sub>8</sub>halocycloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>alkoxyC<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>3</sub>-C<sub>8</sub>cycloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio, C<sub>3</sub>-C<sub>8</sub>cycloalkylthio, C<sub>1</sub>-C<sub>12</sub>haloalkylthio, C<sub>1</sub>-C<sub>12</sub>alkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfinyl, C<sub>1</sub>-C<sub>12</sub>haloalkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfinyl, C<sub>1</sub>-C<sub>12</sub>alkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfonyl, C<sub>1</sub>-C<sub>12</sub>haloalkylsulfonyl and C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfonyl,

Art Unit: 1623

C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfonyl, C<sub>1</sub>-C<sub>12</sub>haloalkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfonyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, -N(R<sub>6</sub>)<sub>2</sub>, wherein the two R<sub>6</sub> are independent of each other; -C(=O)R<sub>7</sub>, -O-C(=O)R<sub>8</sub>, -NHC(=O)R<sub>7</sub>, -S-C(=S)R<sub>8</sub>, -P(=O)(OC<sub>1</sub>-C<sub>6</sub>alkyl)<sub>2</sub>, -S(=O)<sub>2</sub>R<sub>11</sub>; -NH-S(=O)<sub>2</sub>R<sub>11</sub>, -OC(=O)-C<sub>1</sub>-C<sub>6</sub>alkyl-S(=O)<sub>2</sub>R<sub>11</sub>; ~~aryl, benzyl, heterocyclyl, aryloxy, benzyloxy, heterocyclloxy, arylthio, benzylthio, heterocyclthio;~~ and also aryl, heterocyclyl, aryloxy, benzyloxy, heterocyclloxy, arylthio, benzylthio or heterocyclthio, each of which may be mono- to pentasubstituted by substituents selected from the group consisting of OH, halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>haloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio, C<sub>1</sub>-C<sub>12</sub>haloalkylthio, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, dimethylamino-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, phenoxy, phenyl-C<sub>1</sub>-C<sub>6</sub>alkyl, methylenedioxy, -C(=O)R<sub>7</sub>, -O-C(=O)-R<sub>8</sub>, -NH-C(=O)R<sub>8</sub>, -N(R<sub>10</sub>)<sub>2</sub>, wherein the two R<sub>10</sub> are independent of each other; C<sub>1</sub>-C<sub>6</sub>alkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>haloalkylsulfinyl, C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfinyl, C<sub>1</sub>-C<sub>6</sub>alkylsulfonyl, C<sub>3</sub>-C<sub>8</sub>cycloalkylsulfonyl, C<sub>1</sub>-C<sub>6</sub>haloalkylsulfonyl and C<sub>3</sub>-C<sub>8</sub>halocycloalkylsulfonyl;

R<sub>6</sub> is H, C<sub>1</sub>-C<sub>8</sub>alkyl, hydroxy-C<sub>1</sub>-C<sub>8</sub>alkyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, phenyl, benzyl, -C(=O)R<sub>7</sub>, or -CH<sub>2</sub>-C(=O)-R<sub>7</sub>;

R<sub>7</sub> is H, OH, SH, -N(R<sub>10</sub>)<sub>2</sub>, wherein the two R<sub>10</sub> are independent of each other; C<sub>1</sub>-C<sub>24</sub>alkyl, C<sub>2</sub>-C<sub>12</sub>alkenyl, C<sub>1</sub>-C<sub>8</sub>hydroxyalkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>haloalkoxy, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>12</sub>alkylthio, C<sub>2</sub>-C<sub>8</sub>alkenyloxy, C<sub>2</sub>-C<sub>8</sub>alkynyloxy, NH-C<sub>1</sub>-C<sub>6</sub>alkyl-C(=O)R<sub>9</sub>, -N(C<sub>1</sub>-C<sub>6</sub>alkyl)-C<sub>1</sub>-C<sub>6</sub>alkyl-C(=O)-R<sub>9</sub>, -O-C<sub>1</sub>-C<sub>2</sub>alkyl-C(=O)R<sub>9</sub>, -C<sub>1</sub>-C<sub>6</sub>alkyl-S(=O)<sub>2</sub>R<sub>9</sub>; ~~aryl, benzyl, heterocyclyl, aryloxy, benzyloxy, heterocyclloxy;~~ or aryl, benzyl, heterocyclyl, aryloxy, benzyloxy or heterocyclloxy, each of which are unsubstituted or mono- to trisubstituted in the ring independently of one another by halogen, nitro, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub>haloalkyl or C<sub>1</sub>-C<sub>6</sub>haloalkoxy;

R<sub>8</sub> is H, C<sub>1</sub>-C<sub>24</sub>alkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>hydroxyalkyl, C<sub>2</sub>-C<sub>8</sub>alkenyl, C<sub>2</sub>-C<sub>8</sub>alkynyl, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, N(R<sub>10</sub>)<sub>2</sub>, wherein the two R<sub>10</sub> are independent of each other; -C<sub>1</sub>-C<sub>6</sub>alkyl-C(=O)R<sub>10</sub>, -C<sub>1</sub>-C<sub>6</sub>alkyl-S(=O)<sub>2</sub>R<sub>9</sub>, ~~aryl, benzyl, heterocyclyl;~~ or aryl, benzyl or heterocyclyl, each of which may be mono- to trisubstituted by substituents selected from the group consisting of

Art Unit: 1623

of OH, halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>haloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio and C<sub>1</sub>-C<sub>12</sub>haloalkylthio;

R<sub>9</sub> is H, OH, C<sub>1</sub>-C<sub>24</sub>alkyl which is optionally substituted with OH, or -S(=O)<sub>2</sub>-C<sub>1</sub>-C<sub>6</sub>alkyl; C<sub>1</sub>-C<sub>12</sub>alkenyl, C<sub>1</sub>-C<sub>12</sub>alkynyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>6</sub> alkoxy-C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkoxy-C<sub>1</sub>-C<sub>6</sub>alkoxy, C<sub>2</sub>-C<sub>8</sub>alkenyloxy, aryl, aryloxy, benzyloxy, heterocyclyl, heterocyclyloxy or -N(R<sub>10</sub>)<sub>2</sub>, wherein the two R<sub>10</sub> are independent of each other;

R<sub>10</sub> is H, C<sub>1</sub>-C<sub>6</sub>alkyl, which is optionally substituted with one to five substituents selected from the group consisting of halogen, C<sub>1</sub>-C<sub>6</sub>alkoxy, hydroxy and cyano; C<sub>1</sub>-C<sub>8</sub>-cycloalkyl, aryl, benzyl, heterocyclyl; or aryl, benzyl or heterocyclyl, each of which may be ~~are~~ mono- to trisubstituted by substituents selected from the group consisting of OH, halogen, CN, NO<sub>2</sub>, C<sub>1</sub>-C<sub>12</sub>alkyl, C<sub>1</sub>-C<sub>12</sub>haloalkyl, C<sub>1</sub>-C<sub>12</sub>alkoxy, C<sub>1</sub>-C<sub>12</sub>haloalkoxy, C<sub>1</sub>-C<sub>12</sub>alkylthio and C<sub>1</sub>-C<sub>12</sub>haloalkylthio;

or, an E/Z isomer, E/Z isomer mixture and/or tautomer thereof, or a salt thereof.

Claim 8 (canceled).

## **DETAILED ACTION**

Claims 1, 2 and 9-22 directed to an allowable product. Pursuant to the procedures set forth in MPEP § 821.04(B), claims 3, 4 and 7, directed to the process of making or using an allowable product, previously withdrawn from consideration as a result of a restriction requirement, are hereby rejoined and fully examined for patentability under 37 CFR 1.104.

Because all claims previously withdrawn from consideration under 37 CFR 1.142 have been rejoined, **the restriction requirement as set forth in the Office action mailed on April 2, 2009 is hereby withdrawn**. In view of the withdrawal of the restriction requirement as to the rejoined inventions, applicant(s) are advised that if any claim presented in a continuation or divisional application is anticipated by, or includes all the limitations of, a claim that is allowable in the present application, such claim may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Once the restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. See *In re Ziegler*, 443 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

## **REASONS FOR ALLOWANCE**

Applicant's amendments, filed 08/31/09 have overcome the rejections made under 35 U.S.C. 112, second paragraph and under 35 U.S.C. 103(a) in the office action mailed 04/30/09.

The following is an examiner's statement of reasons for allowance: The examiner has found claims 1-4, 7 and 9-22 to be unobvious over the prior art of record and therefore to be allowable over the prior art of record. The present invention relates to a compound of a given formula, an E/Z isomer, E/Z isomer mixture and/or tautomer thereof, or a salt thereof. Also, the invention relates to a method of preparing and using a composition comprising said compound. The compound or composition of the present invention is not taught or suggested in the prior art and is not obvious over the prior art. Also, the method of preparation and use of said composition are not taught or suggested in the prior art and are unobvious over the prior art. For example, the compounds of the present invention are structurally different to the compounds of prior art documents and these differences are not suggested in the prior art, nor are obvious over the prior art.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

### ***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michael C. Henry whose telephone number is 571-272-0652. The examiner can normally be reached on 8.30am-5pm; Mon-Fri. If attempts to reach the

examiner by telephone are unsuccessful, the examiner's supervisor, Shaojia A. Jiang can be reached on 571-272-0627. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Michael C. Henry  
December 15, 2009.

/Shaojia Anna Jiang/  
Supervisory Patent Examiner  
Art Unit 1623